Tromsø, Norway, December 19, 2023 - ArcticZymes Technologies ASA (OSE: AZT)
enters into an agreement with Biomatter (Biomatter Designs UAB) to develop new
enzyme-based products.

ArcticZymes Technologies (AZT) has entered a partnership agreement with
Biomatter, a leading enzyme design company. Leveraging Biomatter's AI-driven
Intelligent Architecture[TM] platform, the companies will co-develop new and
improved products for AZT's enzyme portfolio. The first focus project will be to
explore the SAN portfolio in terms of new functions, properties and IP.

The Intelligent Architecture[TM] platform combines generative AI and physical
modelling to address the current limitations of enzyme engineering accuracy and
time. The unique capabilities offered by the platform enables the design of
enzymes with previously unattainable functions and properties. By leveraging
this technology and Biomatter's expertise, AZT will be able to expand its
offering towards new and existing customers in both the molecular tools and
biomanufacturing businesses.

Michael Akoh, CEO of ArcticZymes said:

"Working with Biomatter is a very exciting step in exploring alternatives to
classic protein design methods. This partnership enhances ArcticZymes
biotechnology toolbox and increases our innovation capabilities. It will play a
pivotal role in accelerating additions to our product portfolio. At the same
time, it is in line with our strategy to seek partnership opportunities across
the value chain to create long term growth"

Laurynas Karpus, co-founder and CEO of Biomatter said:

"ArcticZymes has been a long-standing enzyme supply leader, renowned for its
unique enzyme portfolio. We're excited to collaborate with AZT, harnessing our
Intelligent ArchitectureT platform to explore new frontiers in life sciences
enzymes, and to further expand AZT's capabilities and offerings."

For more information, please contact:

ArcticZymes Technologies
CEO, Michael Akoh         Tel: +46 70 262 3715
                            ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
The company is listed on the Oslo Stock Exchange since 2005 as ArcticZymes
Technologies under the [AZT] ticker. Its headquarters are based in Tromsø,
Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents. For more information, please visit the website:
www.arcticzymes.com.